• Thu news: Industry M&A volume down 8% over 2023. Pfizer’s Ibrance improves breast cancer survival. Lonza shedding capsule biz. AZ’s Lynparza in early breast cancer. Trump wants childhood vaccine discussion. See more on our front page

Idorsia contract

Quote






Yes, people are losing their jobs..and the territories that aren't producing are not hiring new reps...why? Because its the territory that sucks...not the reps. Idorsia has screwed over so many people with their terrible overhiring, micromanaging and ever changing marketing strategy. Support the ones struggling, they are here for the money, not this product!
 






As the industry continues it's decline (pharma sales continues to go the way of the dinosaur as the industry moves to a digital marketing business model), here are some of the major factors that have negatively impacted the job, and experience, of the typical pharma rep (reps may have experienced some of this in years past, but it is much worse today): 1. Poor access to providers (your customers don't want to see you and have created policies that make seeing them very difficult or impossible), 2. Micromanagement (monitored, tracked, busy work/reports, etc. - lack of autonomy), 3. Bad management and/or negative company culture (pervasive in an industry where sociopathy is often rewarded and celebrated - many managers and many of your colleagues exhibit sociopathic personality traits), 4. Stress (refer to factors previously stated, plus unrealistic sales goals), 5. Lack of respect (pharma reps often get no respect from the general public, providers, and office staff), 6. No job stability (the average rep will be changing jobs once every two years on average - contracts end abruptly and often sooner than expected, layoffs occur frequently with manufacturers, and bad managers frequently target reps in their districts/regions to put on PIPs, make miserable, and force out). Once out, it typically takes months to land another gig that is likely to only last 12-24 months, and if you're over the age of 45 it may take longer or become impossible.

Regarding contract reps (reps with CSO's), expect the much of the above to apply even more so than if you're a rep employed by a manufacturer. Job insecurity is built into the contract model, and contract reps are still considered low-status in the industry, a reputation that is not deserved as many contract reps are hard-working, intelligent, driven people who have worked for manufacturers in the past, are experienced, and have achieved excellent results. Also, contract reps tend to receive lower compensation vs their manufacturer counterparts and generally no severance when the contract ends - another insult to the contract rep. There are still newbies who are hungry to work in the industry, and there are more displaced experienced reps than ever who want to continue to ride the roller-coaster of Pharma, so CSO's and Manufacturers have no problem finding candidates willing to volunteer for the often painful employment opportunities they offer. In summary, yes, things have changed and this isn't the industry of the 1990s or the early-mid 2000's. This is the typical reality of Pharma sales in 2022. I do not recommend this career choice.
 






Idorsia is making great progress with the transformation into a commercial company. QUVIVIQ will soon be the leading branded insomnia medication in the US in terms of new prescriptions. The increased volume following the direct-to-consumer campaign supports the ongoing negotiations to secure reimbursement. We are just weeks away from a first-in-class product launch in Europe, and the positive data in Japan means that we are well on track to making daridorexant a global product for patients with insomnia. With such a long patent life ahead, QUVIVIQ will deliver long-term growth and support the advancement of our other innovations.
 






Simon Jose, Chief Commercial Officer of Idorsia, commented:
“I’m determined that patients will get to benefit from our innovation by making QUVIVIQ a leading insomnia medication on a global basis. The growth in demand of QUVIVIQ in the US means that we are close to becoming the leading branded insomnia medication in new-to-brand prescriptions, only 6 months after launch. While I'm pleased this milestone is imminent, this is just the beginning for QUVIVIQ. Our marketing efforts, including direct-to-consumer advertising, are generating new patient starts and we are seeing an increasing number of refills for patients who have started QUVIVIQ. The increase in demand provides a good basis to support our negotiations with payors. We are also just weeks away from the launch of QUVIVIQ in Germany and Italy, which will mark the availability of the first and only DORA in Europe.
 






Simon Jose, Chief Commercial Officer of Idorsia, commented:
“I’m determined that patients will get to benefit from our innovation by making QUVIVIQ a leading insomnia medication on a global basis. The growth in demand of QUVIVIQ in the US means that we are close to becoming the leading branded insomnia medication in new-to-brand prescriptions, only 6 months after launch. While I'm pleased this milestone is imminent, this is just the beginning for QUVIVIQ. Our marketing efforts, including direct-to-consumer advertising, are generating new patient starts and we are seeing an increasing number of refills for patients who have started QUVIVIQ. The increase in demand provides a good basis to support our negotiations with payors. We are also just weeks away from the launch of QUVIVIQ in Germany and Italy, which will mark the availability of the first and only DORA in Europe.
 


















Bankpas said:
Idorsia is making great progress with the transformation into a commercial company. QUVIVIQ will soon be the leading branded insomnia medication in the US in terms of new prescriptions. The increased volume following the direct-to-consumer campaign supports the ongoing negotiations to secure reimbursement. We are just weeks away from a first-in-class product launch in Europe, and the positive data in Japan means that we are well on track to making daridorexant a global product for patients with insomnia. With such a long patent life ahead, QUVIVIQ will deliver long-term growth and support the advancement of our other innovations.
Click to expand...

Cool, They must be close to rolling contract reps to being direct Idorsia reps with the overwhelming success of Quviviq!
 












anonymous said:
As the industry continues it's decline (pharma sales continues to go the way of the dinosaur as the industry moves to a digital marketing business model), here are some of the major factors that have negatively impacted the job, and experience, of the typical pharma rep (reps may have experienced some of this in years past, but it is much worse today): 1. Poor access to providers (your customers don't want to see you and have created policies that make seeing them very difficult or impossible), 2. Micromanagement (monitored, tracked, busy work/reports, etc. - lack of autonomy), 3. Bad management and/or negative company culture (pervasive in an industry where sociopathy is often rewarded and celebrated - many managers and many of your colleagues exhibit sociopathic personality traits), 4. Stress (refer to factors previously stated, plus unrealistic sales goals), 5. Lack of respect (pharma reps often get no respect from the general public, providers, and office staff), 6. No job stability (the average rep will be changing jobs once every two years on average - contracts end abruptly and often sooner than expected, layoffs occur frequently with manufacturers, and bad managers frequently target reps in their districts/regions to put on PIPs, make miserable, and force out). Once out, it typically takes months to land another gig that is likely to only last 12-24 months, and if you're over the age of 45 it may take longer or become impossible.

Regarding contract reps (reps with CSO's), expect the much of the above to apply even more so than if you're a rep employed by a manufacturer. Job insecurity is built into the contract model, and contract reps are still considered low-status in the industry, a reputation that is not deserved as many contract reps are hard-working, intelligent, driven people who have worked for manufacturers in the past, are experienced, and have achieved excellent results. Also, contract reps tend to receive lower compensation vs their manufacturer counterparts and generally no severance when the contract ends - another insult to the contract rep. There are still newbies who are hungry to work in the industry, and there are more displaced experienced reps than ever who want to continue to ride the roller-coaster of Pharma, so CSO's and Manufacturers have no problem finding candidates willing to volunteer for the often painful employment opportunities they offer. In summary, yes, things have changed and this isn't the industry of the 1990s or the early-mid 2000's. This is the typical reality of Pharma sales in 2022. I do not recommend this career choice.
Click to expand...

Great post and very accurate! I’m thankful to be near retirement and will not need to rely on this industry much longer for income.
 
















































My manager told me today I am being given the choice to resign or be terminated. Disappointed they are not calling this what it is, a downsizing. If I am a capable enough rep to be considered for future opportunities with Syneos if I resign, and still be considered in good standing with Syneos, why am I a rep that is being terminated from this position? I have never experience anything like this in my career.
 






anonymous said:
My manager told me today I am being given the choice to resign or be terminated. Disappointed they are not calling this what it is, a downsizing. If I am a capable enough rep to be considered for future opportunities with Syneos if I resign, and still be considered in good standing with Syneos, why am I a rep that is being terminated from this position? I have never experience anything like this in my career.
Click to expand...

Did your manager give you a timeline as to when this would occur?
 






Top Bottom
Back
Quote